What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2025-05-15 compared with 2024-11-19 · 46 added, 30 removed, 4 unchanged (95% of the section changed)

Other Information

During the three months ended September 30, 2024,

the Company’s Board of Directors adopted an Insider Trading Policy which applies to the Company’s officers, directors, employees

and consultants, a copy of which is attached hereto as Exhibit 19.1, to this Quarterly Report on Form 10-Q and incorporated herein by

following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report.

Klotho Neurosciences, Inc.

Insider Trading Policy

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of Principal Accounting and Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of Principal Executive Officer Pursuant to 18 U.S.C.

Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Certification of Principal Accounting and Financial Officer Pursuant to 18 U.S.C.

Insider Trading Arrangements and Policies

During the quarter ended March 31, 2025, none

of the Company’s directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement”

or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, that was intended to satisfy

the affirmative defense conditions of Rule 10b5-1(c).

The following exhibits are filed as part of, or

incorporated by reference into, this Quarterly Report.

Neurosciences, Inc.

Insider Trading Policy (incorporated by reference to Exhibit 19.1 filed by Klotho Neurosciences, Inc.’s

on Form 10-Q filed with the SEC on November 19, 2024).

Certification

of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section

302 of the Sarbanes-Oxley Act of 2002

Certification

of Principal Accounting and Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant

to Section 302 of the Sarbanes-Oxley Act of 2002

Certification

of Principal Executive Officer Pursuant to 18 U.S.C.

Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of

XBRL Instance Document

XBRL Taxonomy Extension Schema Document

XBRL Taxonomy Extension Calculation Linkbase Document

XBRL Taxonomy Extension Definition Linkbase Document

XBRL Taxonomy Extension Labels Linkbase Document

XBRL Taxonomy Extension Presentation Linkbase Document

Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)

Certification

of Principal Accounting and Financial Officer Pursuant to 18 U.S.C.

Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley

policy (incorporated by reference to Exhibit 97.1 filed by Redwoods on Form 10-K filed by the Registrant on April 17, 2024).

Inline XBRL Instance Document

Inline XBRL Taxonomy Extension Schema Document

Inline XBRL Taxonomy Extension Calculation

Linkbase Document

Inline XBRL Taxonomy Extension Definition

Linkbase Document

Inline XBRL Taxonomy Extension Labels Linkbase

Inline XBRL Taxonomy Extension Presentation

Linkbase Document

Cover Page Interactive Data File (Embedded

within the Inline XBRL document and included in Exhibit)

Filed herewith.

Furnished herewith.

This certification is being furnished solely to accompany this report pursuant to 18 U.S.C.

Section 1350, and is not being

filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings

of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned thereunto duly authorized.

KLOTHO NEUROSCIENCES,

November 19, 2024

Executive Officer

Executive Officer)

November 19, 2024

Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Filed previously.

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KLOTHO NEUROSCIENCES, INC.

/s/ Joseph A.

Chief Executive Officer

(Principal Executive Officer)

/s/ Jeffrey LeBlanc

Jeffrey LeBlanc

Financial Officer

Accounting Officer)

Chief Financial Officer

(Principal Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information